RAMM Pharma Corp. RAMM
CNSX
| 07/31/2026 | 04/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 33.96% | -9.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 33.96% | -9.39% | |||
| Cost of Revenue | 281.17% | -16.46% | |||
| Gross Profit | -89.01% | -5.40% | |||
| SG&A Expenses | 1.20% | -10.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 51.72% | 163.64% | |||
| Total Operating Expenses | 18.81% | -10.49% | |||
| Operating Income | -15.31% | 10.75% | |||
| Income Before Tax | -214.65% | 63.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -214.65% | 63.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -214.65% | 63.07% | |||
| EBIT | -15.31% | 10.75% | |||
| EBITDA | -14.09% | 9.97% | |||
| EPS Basic | -211.76% | 63.04% | |||
| Normalized Basic EPS | -209.09% | 70.27% | |||
| EPS Diluted | -211.76% | 63.04% | |||
| Normalized Diluted EPS | -209.09% | 70.27% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||